Improving CD38 antibody therapy in multiple myeloma by enhancing effector cell-mediated killing mechanisms

被引：0
|
作者：
Eichholz, K. M. [1 ,2 ]
Roesner, T. [1 ,2 ]
Burger, R. [1 ,2 ]
Klausz, K. [1 ,2 ]
Otte, A. [1 ,2 ]
Valerius, T. [1 ,2 ]
Schewe, D. M. [2 ,3 ]
Gramatzki, M. [1 ,2 ]
Peipp, M. [1 ,2 ]
Kellner, C. [1 ,2 ]
机构：
[1] Christian Albrechts Univ Kiel, Dept Med 2, Div Stem Cell Transplantat & Immunotherapy, Kiel, Germany
[2] Univ Hosp Schleswig Holstein, Kiel, Germany
[3] Christian Albrechts Univ Kiel, ALL BFM Study Grp, Pediat Hematol Oncol, Kiel, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V412
引用
收藏
页码：137 / 137
页数：1
相关论文
共 50 条
  • [31] Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
    Grandclement, C.
    Estoppey, C.
    Dheilly, E.
    Panagopoulou, M.
    Monney, T.
    Dreyfus, C.
    Loyau, J.
    Labanca, V.
    Drake, A.
    De Angelis, S.
    Rubod, A.
    Frei, J.
    Caro, L. N.
    Blein, S.
    Martini, E.
    Chimen, M.
    Matthes, T.
    Kaya, Z.
    Edwards, C. M.
    Edwards, J. R.
    Menoret, E.
    Kervoelen, C.
    Pellat-Deceunynck, C.
    Moreau, P.
    Mbow, M. L.
    Srivastava, A.
    Dyson, M. R.
    Zhukovsky, E. A.
    Perro, M.
    Sammicheli, S.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [32] Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma
    de la Puente, Pilar
    Luderer, Micah J.
    Federico, Cinzia
    Jin, Abbey
    Gilson, Rebecca C.
    Egbulefu, Christopher
    Alhallak, Kinan
    Shah, Shruti
    Muz, Barbara
    Sun, Jennifer
    King, Justin
    Kohnen, Daniel
    Salama, Noha Nabil
    Achilefu, Samuel
    Vij, Ravi
    Azab, Abdel Kareem
    JOURNAL OF CONTROLLED RELEASE, 2018, 270 : 158 - 176
  • [33] Daratumumab Impairs Myeloma Cell Adhesion Mediated Drug Resistance through CD38 Internalization
    Ghose, Jayeeta
    Terrazas, Cesar
    Viola, Domenico
    Caserta, Enrico
    Krishnan, Amrita
    Hofmeister, Craig C.
    Satoskar, Abhay
    Pichiorri, Flavia
    BLOOD, 2016, 128 (22)
  • [34] CHARACTERIZATION OF CELL-MEDIATED AND ANTIBODY-DEPENDENT EFFECTOR MECHANISMS WITHIN SOLID TUMORS
    HASKILL, JS
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1977, 6 (6-7) : 706 - 706
  • [35] NATURE OF EFFECTOR CELLS RESPONSIBLE FOR ANTIBODY-DEPENDENT CELL-MEDIATED KILLING OF CRYPTOCOCCUS-NEOFORMANS
    DIAMOND, RD
    ALLISON, AC
    INFECTION AND IMMUNITY, 1976, 14 (03) : 716 - 720
  • [36] Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma
    Lee, Hyun Tae
    Kim, Yujin
    Park, Ui Beom
    Jeong, Tae Jun
    Lee, Sang Hyung
    Heo, Yong-Seok
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021, 536 : 26 - 31
  • [37] The clinical relevance of the CD38 positive cell populations, in the bone marrow of patients with multiple myeloma
    Reiter, WW
    Brandhorst, D
    Muer, M
    Hopp, C
    BLOOD, 1996, 88 (10) : 3594 - 3594
  • [38] The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity
    Ono, K
    Ohtomo, T
    Yoshida, K
    Yoshimura, Y
    Kawai, S
    Koishihara, Y
    Ozaki, S
    Kosaka, M
    Tsuchiya, M
    MOLECULAR IMMUNOLOGY, 1999, 36 (06) : 387 - 395
  • [39] Activated T cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell malignancies
    Mihara, Keichiro
    Yanagihara, Kazuyoshi
    Takigahira, Misato
    Ochiya, Takahiro
    Imai, Chihaya
    Kitanaka, Akira
    Takihara, Yoshihiro
    Kimuna, Akiro
    BLOOD, 2007, 110 (11) : 696A - 696A
  • [40] CD38 x ICAM1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma
    Chen, Xiaocheng
    Wong, Oi Kwan
    Post, Leonard
    BLOOD, 2021, 138
12345